iiinova — where your digital self keeps evolving

David Aggen, MD @davidaggen.bsky.social · 13/01/2026

We didn’t get to highlight two important trials for metastatic UC with pure variant histologic features nearly enough. 🔹 ICONIC (nivo/ipi/cabo): clinicaltrials.gov/study/NCT038... 🔹 EV + Pembro IIT (Emory): www.clinicaltrials.gov/study/NCT057...

clinicaltrials.gov

ClinicalTrials.gov

000

David Aggen, MD @davidaggen.bsky.social · 13/01/2026

Really enjoyed talking with the original Uromigos Brian Rini & Tom Powles about variant histology bladder cancer. 🎧 Uromigos Episode 472 — podcasts.apple.com/es/podcast/e... worth a listen #BladderCancer

podcasts.apple.com

Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer

Episodio de podcast · The Uromigos · 12/01/2026 · 27 min

010

David Aggen, MD @davidaggen.bsky.social · 25/10/2025

Variant histologies in bladder cancer are like different genres of music Same stage - different openers and headliners Watch here ➡️ x.com/uromigos/sta...

010

David Aggen, MD @davidaggen.bsky.social · 25/04/2025

If you are looking for updates in #GU, join us in NYC on 4/30 for @OncLive #Stateofthescience summit. Free for healthcare professionals to register here! shorturl.at/uTCUA

000

David Aggen, MD @davidaggen.bsky.social · 15/02/2025

Very proud of rising star fellow Aditi Gupta for her work on immune profiling in mUC patients receiving EV #ASCOGU @MSKCancerCenter #GU25

041

David Aggen, MD @davidaggen.bsky.social · 15/02/2025

Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with ORR of 41% DCR 90% 50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor @MSKCancerCenter #ASCOGU #GU25

032

David Aggen, MD @davidaggen.bsky.social · 14/02/2025

Excited to hear a review of the DV + PD-1 from our MSK Cancer Center colleague Scot Niglio #ASCOGU #GU25 Path Cr rate of 84.6% in HER2 3+

021

Reposted by David Aggen, MD

Tian Zhang, MD @tiansterzhangmd.bsky.social · 14/02/2025

#MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing #Alliance #MODERN trial! @ascocancer.bsky.social #GU25

064

David Aggen, MD @davidaggen.bsky.social · 13/02/2025

Congrats to Vinod Balachandran, a surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK, for being named to the inaugural edition of the @washingtonpost's Next 50, a list of up-and-coming changemakers shaping society in 2025. bit.ly/3CMJhN6

bit.ly

Memorial Sloan Kettering Cancer Center Surgeon-Scientist, Vinod Balachandran, MD, Named to The Washington Post Next 50

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce The Washington Post has named Vinod Balachandran, MD, surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK...

000

Reposted by David Aggen, MD

Toni Choueiri, MD @drchoueiri.bsky.social · 05/02/2025

Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer www.nature.com/articles/s41... This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab www.nature.com/articles/s41...

12915

David Aggen, MD @davidaggen.bsky.social · 24/01/2025

Gopa Iyer discussing the potential for platinum following EV + pembro for advanced UC #AUC3 #bladdercancer

021

Reposted by David Aggen, MD

Tian Zhang, MD @tiansterzhangmd.bsky.social · 24/01/2025

This GU oncology family — wonderful first #AUC3 consensus conference! @drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social

083

David Aggen, MD @davidaggen.bsky.social · 24/01/2025

At #AUC3 this A.M. discussing what’s next for treatment of NMIBC and treatment of variant histology UC - Gopa Iyer and Josh Meeks chairing session this AM with talks from Andrea Necchi, Michiel Van der Heijden, and Roger Li #bladdercancer

131

David Aggen, MD @davidaggen.bsky.social · 23/01/2025

Dr. Marie Carlo discussing the role of NGS and germline testing for RCC and non-clear cell RCC @MSKCancerCenter #auc3 #kidneycancer @BradMcG04 chairing session

010

David Aggen, MD @davidaggen.bsky.social · 23/01/2025

Dr. Motzer reviewing the treatment landscape for advanced kidney cancer. Discussing when is the right time to introduce belzutifan. @MSKCancerCenter #AUC3 #kidneycancer

000

David Aggen, MD @davidaggen.bsky.social · 23/01/2025

Stellar overview of cytoreductive nephrectomy in the era of combination immunotherapy by Ari Hakimi #auc3 #kidneycancer

010

David Aggen, MD @davidaggen.bsky.social · 13/12/2024

Innovative therapies in GU cancers: Promising targets in #Urothelial and #Kidney cancer.- BL-B01D1: A bispecific ADC (EGFR/HER3) with a 40% response rate in advanced urothelial cancer. - NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe

bit.ly

Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg

Alicia Morgans speaks with Jonathan Rosenberg about two novel therapies presented at ESMO 2024. The discussion centers on BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in adva...

040

Reposted by David Aggen, MD

Nima Sharifi MD @nimasharifimd.bsky.social · 11/12/2024

My heart sank when I heard the news that Felix Feng has passed away. Felix was such a gentle and uplifting force for so many of us who work in the same field - and for anyone he touched. Although he has left us, his impact will be felt forever. ow.ly/Uc3H50TSBiC

ow.ly

I just helped save a life

You can save one, too. Donate now.

2268

Reposted by David Aggen, MD

Laura Caba @lauracaba.bsky.social · 04/12/2024

Rich Matulewicz #SUO24 “Blockbuster New Therapy for Cancer…. Smoking Cessation “. @joshmeeks.bsky.social @yawnyame.bsky.social @wandering-gu.bsky.social

0106

David Aggen, MD @davidaggen.bsky.social · 04/12/2024

#SUO24 Implementing Smoking Cessation in the Urologic Oncology Setting @RichMatulewicz Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis @urotoday

020

David Aggen, MD @davidaggen.bsky.social · 04/12/2024

@RichMatulewicz representing @UrologyMSK at the #SUO24 discussing clinical evolution in the management of seminoma.

030

Reposted by David Aggen, MD

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 27/11/2024

AI has a huge potential in #BladderCancer for diagnosis, prognostic and predictive assessment Some questions remain to be answered related to: ▶️ Heterogeneity of disease ▶️ Interreader variability of pathology assessment ▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social

095

Reposted by David Aggen, MD

Tim Robinson @drtimrobinson.bsky.social · 26/11/2024

Nice review! I’m sure we will have combination strategies in the clinic on the next few years but must balance efficacy with cost/side effect profiles

052

Reposted by David Aggen, MD

Anne Wojcicki @annewoj.bsky.social · 26/11/2024

As we embark on Thanksgiving week I want to take a moment to reflect on this year and my family. Unfortunately I lost my sister to lung cancer in August. blog.youtube/inside-youtu...

blog.youtube

From Susan

1135